PTS-ID: Developing Precision Behavioral Health Diagnostics for PTSD

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

In 2013, a separate diagnosis of PTSD was introduced into the DSM-V to mitigate the well-known issue of accurately differentiating between PSTD and other psychiatric disorders.  In addition to these advancements, the field continuous to develop more quantifiable methodologies, such as biological markers to strengthen the tool set available to clinicians enabling them to distinguish between overlapping conditions. For example, PTSD symptom profile overlaps with those of common mental conditions, such as mood disorders, anxiety disorders, and substance abuse, the most common being Major Depressive Disorder. Reasons for why it is important to make a clearer distinction between these two disorders is due to the treatment options available to both. For PTSD, Cognitive Behavior Therapy (CBT) has consistently been found to be the most effective treatment both in the short term and the long term. Whereas for MDD, monotherapy with antidepressants is recognized by current guidelines as an effective first-line treatment for patients with mild, moderate or even severe major depression.  Since PSTD has shown moderate heritability accountability, identifying the genetic factors that contribute to this susceptibility is of great interest for developing a biological diagnostic tool as the similarities of symptoms between PTSD and MDD may be due in part to shared genetic liability. Nevertheless, manifestation of these underlying mechanisms may also vary due to epigenetic factors. Polaris genomics has developed genetic test panels - PTS-ID DNA and Trugen-1 RNA  for PTSD susceptibility and diagnosis, based on the data from prior research studies. Each panel aims to compliment the other by encompassing a multi-omics approach to study the flow of biological information at multiple levels (in this case: genome; epigenome; transcriptome), thus, unraveling the mechanisms underlying the biological condition of interest, resulting in identification of a reliable predictive and diagnostic biomarker tools for more accurate diagnosis and treatment of mental and behavioral health conditions.

Learning Objectives: 

1. Discuss genetic biomarkers related to Post-Traumatic Stress Disorder.

2. Discuss pharmacogenomic biomarkers that impact anti-depressant treatment.

3. Explain how genomics can improve diagnosis and treatment of mental and behavioral health disorders.


Show Resources
You May Also Like
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUL 19, 2022 8:00 AM PDT
JUL 19, 2022 8:00 AM PDT
Date: July 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Traditional liver perfusion procedures are difficult to perform and require extensive training, steady hands, and long-st...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
FEB 24, 2022 10:00 AM PST
C.E. CREDITS
FEB 24, 2022 10:00 AM PST
Date: February 24, 2021 Time: 10:00am (PST), 1:00pm (EST) One of the largest global public health crises is the rise of antimicrobial-resistant infections. Globally, over 700,000 people die...
Loading Comments...
Show Resources